Searched for
ADITYA MEDISALES
Sun Pharma settles fund diversion case with SebiThe move could be a booster for Sun Pharma shares as corporate governance issues have weighed investor sentiment for the past two years.- Aditya Medisales case: Sebi accepts settlement pleas of Sun Pharma, promotersSebi had initiated a probe against Sun Pharma, its managing director Dilip Shanghvi and its directors on the basis of two whistleblower com...
- Firm on pharma, Dilip Shanghvi surrenders NBFC licenceRBI puts on hold Shanghvi Finance's request for core investment company licence.
- Sun Pharmaceuticals to set up an ethics committee to oversee corporate governance-related mattersSudhir Valia to focus more on pursuits outside Sun, but continues to be a valuable resource for the company.
- Shareholders not disadvantaged in transactions with Aditya Medisales: Sun PharmaShanghvi was responding to the concern raised by some investors whether Aditya Medisales has benefited in the past at the cost of Sun Pharm...
- Sebi seeks answers on Sun Pharma’s two issuesA whistle-blower complaint has alleged that the company reportedly dealt with banned traders.
- Got 2 queries from Sebi: Sun PharmaSun Pharma’s shares have been volatile in the last two months.
- Sun to overhaul business practices to allay concernsSun Pharma's domestic formulations biz would be transitioned from Aditya Medisales to a wholly owned arm.
- Sun Pharma changes distributor, gains 5%The stock ended at Rs 418 on Tuesday, emerging as the top gainer on the Sensex.
- CLSA retains buy on Sun Pharma, says valuations are attractiveThe foreign brokerage said valuations of Sun Pharma are attractive given improving business fundamentals.
- Sun Pharma jumps 5% as company clarifies on Suraksha RealtyThe company will make its unit the new distributor for its domestic formulations business.
- Sun Pharma restructures certain business decisions to address corporate governance issuesThe company "unequivocally" denied that it had lent or stood guarantee for Suraksha Realty
- There is no diversion of funds at all: Sudhir Valia, director, Sun PharmaSudhir Valia, brother-in-law of Sun Pharma promoter Dilip Shanghvi, in a telephonic chat with Divya Rajagopal, discusses the issues of Adit...
- Governance concern to remain overhang on Sun Pharma, say analystsBloomberg data showed that of the 41 analysts tracking the stock, 22 have 'buy' ratings.
- Sun Pharma trying to shoot the messenger, not address core issues: Shriram Subramanian, InGovern ResearchEven if they are not hiding, they are not giving a convincing answer, says Subramanian.
- Sun sinks 13% after reports of 2nd whistleblower letterSun complained that such access creates a "great asymmetry in the information circulating between analysts, investors and media, leading to...
- Sun Pharma denies getting new whistleblower complaint, says not privy to contentWe are not privy to the contents of the document being referred, Sun Pharma said.
- Sun Pharma should change the board and come clean: Shriram Subramanian, InGovern Research“Sun Pharma must say they are not going to have any transaction with Aditya Medisales going forward.”
- We are not very negative on Sun Pharma: Ranvir Singh, Systematix SharesCurrently, the share is trading at around 19 to 20 times and I do not see a downside from there, says Singh.
- Investors irked by lack of disclosures at Sun PharmaThe lack of disclosures around non-related party transactions to the tune of Rs 2,200 crore has become a sore spot for investors, who are q...
Load More
